These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 21271294)

  • 1. Free terminal time optimal control problem of an HIV model based on a conjugate gradient method.
    Jang T; Kwon HD; Lee J
    Bull Math Biol; 2011 Oct; 73(10):2408-29. PubMed ID: 21271294
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correlates of cytotoxic T-lymphocyte-mediated virus control: implications for immunosuppressive infections and their treatment.
    Wodarz D; Nowak MA
    Philos Trans R Soc Lond B Biol Sci; 2000 Aug; 355(1400):1059-70. PubMed ID: 11186307
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Taking side effects into account for HIV medication.
    Costanza V; Rivadeneira PS; Biafore FL; D'Attellis CE
    IEEE Trans Biomed Eng; 2010 Sep; 57(9):2079-89. PubMed ID: 20501345
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimized structured treatment interruption for HIV therapy and its performance analysis on controllability.
    Ko JH; Kim WH; Chung CC
    IEEE Trans Biomed Eng; 2006 Mar; 53(3):380-6. PubMed ID: 16532764
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A model predictive control based scheduling method for HIV therapy.
    Zurakowski R; Teel AR
    J Theor Biol; 2006 Jan; 238(2):368-82. PubMed ID: 15993900
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stimulation of HIV-specific cellular immunity by structured treatment interruption fails to enhance viral control in chronic HIV infection.
    Oxenius A; Price DA; Günthard HF; Dawson SJ; Fagard C; Perrin L; Fischer M; Weber R; Plana M; García F; Hirschel B; McLean A; Phillips RE
    Proc Natl Acad Sci U S A; 2002 Oct; 99(21):13747-52. PubMed ID: 12370434
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutation and control of the human immunodeficiency virus.
    Stengel RF
    Math Biosci; 2008 Jun; 213(2):93-102. PubMed ID: 18439629
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dynamic multidrug therapies for HIV: a control theoretic approach.
    Wein LM; Zenios SA; Nowak MA
    J Theor Biol; 1997 Mar; 185(1):15-29. PubMed ID: 9093552
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of prolonged discontinuation of successful antiretroviral therapy on CD4+ T cell decline in human immunodeficiency virus-infected patients: implications for intermittent therapeutic strategies.
    Tebas P; Henry K; Mondy K; Deeks S; Valdez H; Cohen C; Powderly WG
    J Infect Dis; 2002 Sep; 186(6):851-4. PubMed ID: 12198623
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sensitivity analysis of a nonlinear lumped parameter model of HIV infection dynamics.
    Bortz DM; Nelson PW
    Bull Math Biol; 2004 Sep; 66(5):1009-26. PubMed ID: 15294416
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [HIV 1998: eradication dreams?].
    Vernazza PL
    Schweiz Med Wochenschr; 1998 Dec; 128(51-52):2019-22. PubMed ID: 10024999
    [No Abstract]   [Full Text] [Related]  

  • 12. Optimal antiretroviral therapy: HIV-1 treatment strategies to avoid and overcome drug resistance.
    Grant PM; Zolopa AR
    Curr Opin Investig Drugs; 2010 Aug; 11(8):901-10. PubMed ID: 20721832
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A viral load-based cellular automata approach to modeling HIV dynamics and drug treatment.
    Shi V; Tridane A; Kuang Y
    J Theor Biol; 2008 Jul; 253(1):24-35. PubMed ID: 18083195
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Short- and Long-Term Optimal Control of a Mathematical Model for HIV Infection of CD4+T Cells.
    Croicu AM
    Bull Math Biol; 2015 Nov; 77(11):2035-71. PubMed ID: 26493544
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HIV-1 dynamics after transient antiretroviral therapy: implications for pathogenesis and clinical management.
    Phillips AN; McLean A; Johnson MA; Tyrer M; Emery V; Griffiths P; Bofill M; Janossy G; Loveday C
    J Med Virol; 1997 Nov; 53(3):261-5. PubMed ID: 9365893
    [TBL] [Abstract][Full Text] [Related]  

  • 16. RANTES production by T cells and CD8-mediated inhibition of human immunodeficiency virus gene expression before initiation of potent antiretroviral therapy predict sustained suppression of viral replication.
    Fransen S; Copeland KF; Smieja M; Smaill F; Rosenthal KL
    J Infect Dis; 2000 Feb; 181(2):505-12. PubMed ID: 10669333
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monte Carlo estimates of natural variation in HIV infection.
    Heffernan JM; Wahl LM
    J Theor Biol; 2005 Sep; 236(2):137-53. PubMed ID: 16005307
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A multicenter observational study of the potential benefits of initiating combination antiretroviral therapy during acute HIV infection.
    Hecht FM; Wang L; Collier A; Little S; Markowitz M; Margolick J; Kilby JM; Daar E; Conway B; Holte S;
    J Infect Dis; 2006 Sep; 194(6):725-33. PubMed ID: 16941337
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improvement in immune parameters and human immunodeficiency virus-1 viral response in individuals treated with 16alpha-bromoepiandrosterone (HE2000).
    Reading C; Dowding C; Schramm B; Garsd A; Onizuka-Handa N; Stickney D; Frincke J
    Clin Microbiol Infect; 2006 Nov; 12(11):1082-8. PubMed ID: 17002607
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.